Navigation Links
Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth

... with Sales Team Forming and Increased Space, Poised for Market Launch

KIRKLAND, Wash., Aug. 20 /PRNewswire/ -- Pathway Medical Technologies, Inc., which is developing innovative devices for the treatment of arterial disease, today announced that it has hired a VP of Sales, Joseph W. Rafferty, and has started building its sales team in preparation for the introduction of its first product, Pathway PV(TM) Atherectomy System.

Recently Pathway moved from its old 10,000-square-foot facility to a new state-of-the art 51,000-square-foot, cGMP (Good Manufacturing Practices) - compliant manufacturing facility at 10801 120th Ave NE in Kirkland. The new facility boasts a 6,500-square-foot clean room to meet anticipated market demand. Additional 3000-square-feet are available for future expansion purposes. In the last six months the company's staff has grown from 53 to 91, almost doubling the size of the company, and Pathway continues to add employees to prepare for its first product introduction.

Mr. Rafferty, who will be working out of the company's new headquarters, joins the Pathway executive team with more than 25 years of experience in the medical-device industry. He has held senior sales and marketing management positions at companies like ACS/Guidant, where his contributions led to its leadership position in interventional cardiology. In his role as the Midwest Region Sales Manager, he pioneered Guidant's highly successful P3 (price-per- procedure) program, which ultimately redefined the reimbursement model for interventional cardiology.

"Joe brings extensive field sales, sales management and operational management experience to our team. He will be a significant contributor to the success of Pathway's premier new product. He knows how to build a leading sales organization for a category leader," said Pathway CEO and President Tom Clement.

"When you have a product about to launch with all the hallmarks of a category leader, it's exhilarating!" commented Mr. Rafferty. "My first task is to build a formidable and experienced sales team as quickly as possible."

"I am delighted to be joining the Pathway Medical team at such an exciting time. We are well-positioned for terrific growth as we commercialize the Pathway PV Atherectomy System," he said.

About Pathway Medical Technologies, Inc.

Pathway Medical Technologies, Inc. was founded to develop, manufacture and market medical devices for the treatment of arterial disease. The company's initial focus is treating peripheral arterial disease (PAD) more quickly, safely and effectively than existing technologies. An estimated 14 million people are afflicted by PAD in the United States, and that number is projected to grow to over 20 million during the next 10 years. The company's Pathway PV System allows for a minimally invasive procedure designed to restore circulation in the peripheral arteries by removing both hard and soft diseased tissue.

Nine months ago, the company passed a major milestone when it received a $25 million Series B round of financing from five venture capital investors.

Company Contact:

Thomas J. Clement



SOURCE Pathway Medical Technologies, Inc.

Copyright©2007 PR Newswire.

Related biology technology :

1. Assess the In Vivo Activation of Signal Transduction Pathways with PathDetect Reporting Systems
2. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
3. In Vivo Signal Transduction Pathway Reporting Systems
4. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
5. New Fusion Trans-Activator Plasmids for Studying Signal Transduction Pathways
6. Medical College receives $377K to study brain disease
7. Barriers will not stop convergence of medical technologies
8. Medical College team creates website for tracking flu
9. Biomedical engineering conference invites manufacturers
10. Visions: Wade offers straight talk on e-medical records
11. Merge unveils updated medical imaging software
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... --> Accutest Research Laboratories, ... Contract Research Organization (CRO), has formed ... Cancer Center - Temple Health for ... ,     (Photo: ) , ...
(Date:11/25/2015)... Studies reveal the differences in species of bacteria ... for more effective treatment for one of the most commonly ... --> --> Gum disease is one ... relatively little was understood about the bacteria associated with it ... researchers from the WALTHAM Centre for Pet Nutrition together with ...
(Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, Inc. ... participate in a fireside chat discussion at the Piper ... York . The discussion is scheduled for Wednesday, ... .  A replay will be available for ... Stilwell  , Julie NormartVP, Corporate Communications and Business ...
(Date:11/24/2015)... Cepheid (NASDAQ: CPHD ) today announced ... conference, and invited investors to participate via webcast. ... December 1, 2015 at 11.00 a.m. Eastern Time ... December 1, 2015 at 11.00 a.m. Eastern Time ... York, NY      Tuesday, December 1, 2015 at ...
Breaking Biology Technology:
(Date:11/10/2015)... 10, 2015 About signature ... helps to identify and verify the identity of ... as the secure and accurate method of authentication ... particular individual because each individual,s signature is highly ... when dynamic signature of an individual is compared ...
(Date:11/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), the ... entry into the automotive market with a comprehensive and ... of consumer electronics human interface innovation. Synaptics, industry-leading touch ... the automotive industry and will be implemented in numerous ... , Japan , and ...
(Date:11/2/2015)... MENLO PARK, Calif. , Nov. 2, 2015 /PRNewswire/ ... to $9 million to provide preclinical development services to ... Under the contract, SRI will provide scientific expertise, modern ... a wide variety of preclinical pharmacology and toxicology studies ... --> --> The PREVENT Cancer Drug ...
Breaking Biology News(10 mins):